Karen Pekle
Nurse Practitioner · New York, NYNPI 1255412920
Payments from drug & device makers
Across 104 payments — averaging $69.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Sanofi$740
- Karyopharm Therapeutics Inc.$685
- Takeda Pharmaceuticals U.S.A., Inc.$554
- Bristol Myers Squibb$547
- E.r. Squibb & Sons, L.L.C.$491
- plus $1K from 11 others
What the payments were for
- Consulting fees$1,76024%
- Food & beverage$5,01269%
- Education$4506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $3,089 |
| Sanofi | 13 | $740 |
| Karyopharm Therapeutics Inc. | 10 | $685 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $554 |
| Bristol Myers Squibb | 19 | $547 |
| E.r. Squibb & Sons, L.L.C. | 4 | $491 |
| Incyte Corporation | 3 | $335 |
| Legend Biotech USA Inc. | 3 | $195 |
| Sanofi-aventis U.S. LLC | 2 | $172 |
| Pfizer | 4 | $107 |
| GSK | 1 | $100 |
| AstraZeneca | 2 | $54 |
| Amgen | 2 | $49 |
| Argon Medical Devices, Inc. | 1 | $31 |
| Octapharma USA, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Sobi, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,222 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 91 | $2,127,108 |
| RevlimidLenalidomide | 68 | $1,270,766 |
| Lenalidomide | 75 | $1,123,161 |
| ImbruvicaIbrutinib | 13 | $212,243 |
| VenclextaVenetoclax | 18 | $188,095 |
| CalquenceAcalabrutinib Maleate | 11 | $169,916 |
| NinlaroIxazomib Citrate | 12 | $156,109 |
| EliquisApixaban | 32 | $23,531 |
| Entecavir | 14 | $4,782 |
| ValacyclovirValacyclovir Hcl | 152 | $3,974 |
| Fentanyl | 11 | $2,524 |
| Colesevelam Hcl | 13 | $935 |
| Gabapentin | 46 | $714 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $535 |
| Dexamethasone | 19 | $496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $491 | $2,127,10891 claims |
| Bristol Myers SquibbRevlimid | $547 | $1,270,76668 claims |
| AstraZenecaCalquence | $54 | $169,91611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $554 | $156,10912 claims |
| PfizerEliquis | $107 | $23,53132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New York
- Patricia McGoldrickNew York$202K
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Tsz Isabel WongNew York$25K
- Chris BustamanteNew York$22K
- Mayra PozoNew York$14K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.